Please assess the completion status of the following clinical trial:

Trial Title: PEGPH20, Gemicitabine and Nab-Paclitaxel for Pancreatic Ductal Adenocarcinoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Greater than or equal to 18 years old~* Histologically confirmed pancreatic adenocarcinoma~* Borderline resectable disease~* Performance status of Eastern Cooperative Oncology Group (ECOG) of 0-1~* Therapy naïve~* Evaluable disease with either:~* RECIST-defined measurable disease~* An elevated serum CA19-9 \>100 u/ml~* Adequate organ function including:~* Bone marrow: Absolute Neutrophil Count (ANC) ≥1500/mm3, platelets ≥100,000/mm3 and hemoglobin ≥ 9 g/dL~* Hepatic: Serum total bilirubin ≤1.5 x upper limit of normal (ULN), alanine aminotransferase (ALT)/ serum glutamic-pyruvic transaminase (SGPT) and aspartate aminotransferase (AST)/ serum glutamic-oxaloacetic transaminase (SGOT) ≤ 2.5 x ULN.~* Renal: Serum creatinine (sCr) ≤ 1.5 x ULN, or creatinine clearance (Ccr) ≥ 40 mL/min as calculated by the Modified Cockcroft-Gault formula.~* Peripheral neuropathy \< grade 2~* Alkaline phosphatase ≤ 2 times the ULN unless bone metastasis is present in the absence of liver metastasis~Exclusion Criteria:~* Age younger than 18 years old~* Locally advanced or metastatic disease~* Known allergy to hyaluronidase~* Contraindications to prophylactic dose low molecular weight heparin (LMWH) , including~* Patients with recent gastrointestinal bleeding~* History of heparin induce thrombocytopenia on LMWH~* Subjects with previous severe hemorrhagic events on LMWH~* Known contraindications to heparin including:~* Recent central nervous system bleed, intracranial or spinal lesion at high risk for bleeding~* Active bleeding (major): more than 2 units transfused in 24 hours~* Spinal anesthesia/lumbar puncture within the past month~* Chronic, clinically significant measurable bleeding \> 48 hours~* Severe platelet dysfunction (uremia, medications, dysplastic hematopoiesis)~* Recent major operation at high risk for bleeding~* Underlying hemorrhagic coagulopathy High risk for falls (head trauma)~* Presence of metal biliary stents (plastic biliary stents are not an exclusion)~* Known status of HIV which is not well-controlled at the time of study eligibility~* Untreated Hepatitis B infection~* Active infection or antibiotics within 48 hours prior to study~* Currently active second primary malignancy or history of malignancy less than 5 years prior to the time of study eligibility (Patients with history of skin cancers excluding melanoma will be eligible for participation).~* Serious medical comorbidities such as New York Heart Association Class III/IV cardiac disease, uncontrolled cardiac arrhythmias, myocardial infarction over the past 12 months.~* Patients with aneurysm clips, ear implants, spinal nerve stimulators, pacemaker, shrapnel or any other metal in their body (contraindication for MRI scans)~* Known, existing uncontrolled coagulopathy. Patients who have had a venous thromboembolic event (e.g., pulmonary embolism or deep vein thrombosis) requiring anticoagulation are eligible IF: they are appropriately anticoagulated and have not had a Grade 2 or greater bleeding episode in the 3 weeks before Day 1.~* Current use of warfarin (patients will be eligible if warfarin is discontinued and low-molecular weight heparin is used instead).~* Intolerance to dexamethasone~* Prior history of cerebrovascular accident or transient ischemic attack, or pre-existing carotid artery disease.~* Known pregnancy, nursing women or positive pregnancy test.~* Any condition that would preclude informed consent, consistent follow-up and compliance for the study participation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Combination therapy with 1 week Run-In (Type: EXPERIMENTAL): PEGPH20: 3ug/kg on Days 1 and 4~1 cycle = 28 days~PEGPH20: 3ug/kg on Days 1, 8, 15~Gemcitabine: 1000mg/m\^2 on Days 1, 8, 15~Nab-paclitaxel: 125mg/m\^2 on Days 1, 8, 15
- Combination therapy alone (Type: EXPERIMENTAL): 1 cycle = 28 days~PEGPH20: 3ug/kg on Days 1, 8, 15~Gemcitabine: 1000mg/m\^2 on Days 1, 8, 15~Nab-paclitaxel: 125mg/m\^2 on Days 1, 8, 15

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues